Other papers submitted by: Dr Steven Silverstein | Dove Medical Press

News:

Authors are invited to browse Collections that are currently open for submissions Read more

114900

Papers Published

Submit new manuscript

Login to view existing manuscript status

Sign up for Dove Medical Press newsletters

About Dove Medical Press

Open access peer-reviewed scientific and medical journals.

Open Access Promo

Dove Medical Press is a member of the OAI.

Reprints

Bulk reprints for the pharmaceutical industry.

Social Media

Back to User profile » Dr Steven Silverstein

Papers published by Dr Steven Silverstein:

Original Research

Assessing Retinal Thickness and Associations with Cognitive Function in Women with History of Preeclampsia

Ibarra AJ, Phan BN, Silverstein SM, Chhablani J, Snyder V, Rossi EA, Butters MA, Catov JM

Eye and Brain 2026, 18:542082

Published Date: 12 January 2026

Original Research

Highly-accessed

Retinal Microvasculature in Schizophrenia

Silverstein SM, Lai A, Green KM, Crosta C, Fradkin SI, Ramchandran RS

Eye and Brain 2021, 13:205-217

Published Date: 24 July 2021

Review

Highly-accessed

Visual Impairment and Mental Health: Unmet Needs and Treatment Options

Demmin DL, Silverstein SM

Clinical Ophthalmology 2020, 14:4229-4251

Published Date: 3 December 2020

Original Research

Noteworthy comment: This paper is noteworthy because it describes a new tool to assess patients’ perspectives on a serious, often distressing aspect of a chronic mental illness—ie, cognitive impairment associated with schizophrenia. As recommended by the FDA’s guidance on patient-reported outcome (PRO) measures, the multistage development process utilized by the investigators incorporated quantitative and qualitative data from patients and providers. Given the importance to patients of receiving understandable information about their conditions, this new PRO measure may prove valuable in building a therapeutic alliance with patients with schizophrenia. Furthermore, following psychometric validation in an ongoing clinical trial, the measure could define key patient-oriented endpoints for future trials.

Highly-accessed

Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia

Youtube play button

Youtube thumbnail

Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC

Patient Related Outcome Measures 2017, 8:71-81

Published Date: 8 June 2017